April 26th 2024
During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
AP26113 Receives Breakthrough Therapy Designation for NSCLC
October 3rd 2014The highly selective ALK inhibitor AP26113 has been granted a Breakthrough Therapy Designation by the FDA for the treatment of patients with ALK-positive metastatic NSCLC who received prior treatment with crizotinib.
Read More
Low-Risk Stage IV NSCLC Patients Achieve Long-Term Survival After Aggressive Treatment
September 17th 2014Timing of metastatic development, lymph node involvement, and type of disease all factor into the overall survival (OS) rate of patients with stage IV NSCLC, and could offer a potential risk stratification scheme for ablative therapy.
Read More
The Potential Benefit for a Blood-Based Test to Detect a T790M Mutation
September 9th 2014Paul A. Bunn, Jr., MD, Giant of Cancer Care: Lung Cancer, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses the potential benefit for a blood-based test to detect a T790M mutation in lung cancer.
Watch
Evolving Survival Rates in Non-Small Cell Lung Cancer
August 30th 2014Lung cancer remains the leading cause of cancer-related mortality in the United States, despite decreases in lung cancer mortality rates beginning in 1991 for the male population and decreases beginning in 2003 for female population.
Read More
Early-Stage Lung Cancer: Refining Treatment Plans
August 26th 2014The optimal management of patients with early-stage NSCLC remains controversial, and the prospect of exposing an otherwise low-risk patient to potentially toxic chemotherapy based on limited prognostic information remains a problem for many clinicians.
Read More
AstraZeneca Partners With QIAGEN, Roche to Develop Companion Diagnostics for Lung Cancer Drugs
August 11th 2014AstraZeneca has announced new collaborations with QIAGEN and Roche to create 2 separate, noninvasive companion diagnostic tests to be used with 2 of its drugs for NSCLC, gefitinib (IRESSA) and AZD9291.
Read More
Current TKI Therapy Practices and TKI Combinations in Lung Cancer
August 8th 2014James CH Yang, MD, PhD, Professor of Medicine, Deputy Director, Department of Medical Oncology, National Taiwan University Hospital, Director, Cancer Research, Center National Taiwan University College of Medicine, discusses current practices for administering TKI therapy and the potential for TKI combinations.
Watch
Trials of Anti-PD-L1 in NSCLC Are Well Under Way
July 30th 2014Despite standard chemotherapy and the availability of targeted therapies such as bevacizumab, cetuximab, and tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib, and crizotinib, survival rates are far from optimal for patients with NSCLC.
Read More
The Challenges of Identifying Biomarkers in Lung Cancer
July 18th 2014Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses some of the challenges researchers face when it comes to biomarkers in lung cancer.
Watch